RENSSELAER, N.Y.--(BUSINESS WIRE)--ConSynance Therapeutics Inc. announced today that Peter Guzzo, Ph.D., CEO, presented data on the company's Phase I nonalcoholic steatohepatitis (NASH) drug candidate, CSTI-100, at NASH Summit 2018, on April 24 in Boston. CSTI-100 is a selective melanin-concentrating hormone receptor 1 (MCHR1) antagonist that has successfully completed Phase 1 clinical studies in overweight subjects.
In the present study, CSTI-100 was examined in a high fat diet-induced fatty liver disease mouse model and in a western diet plus fructose induced NASH mouse model. The results obtained from both models are consistent with CSTI-100 being an efficacious treatment for NASH. CSTI-100 performed better in these models than two other agents that have shown efficacy in clinical trials for the treatment of NASH. Specifically, these studies demonstrate that chronic treatment with CSTI-100 produces:
- Reductions in key liver inflammatory, fibrosis and injury biomarkers
- Reductions in liver fat (triglycerides and non-esterified fatty acids) and cholesterol
- Improvements in liver histology
- Fat-selective weight loss due to reduction in food intake
- Improvements in glucose tolerance and insulin sensitivity
"We are quite excited by the multiple positive changes in these two animal models of NASH,” said Peter Guzzo, Ph.D. “We believe they indicate CSTI-100 should have a therapeutic effect in human clinical studies and that this therapeutic profile should be attractive to commercialization partners."
About ConSynance Therapeutics, Inc.
ConSynance Therapeutics is a clinical-stage drug development company based in Rensselaer, New York. ConSynance’s pipeline includes innovative treatments for NASH, the orphan disease Prader-Willi syndrome, and irritable bowel syndrome. www.consynance.com